ANCA Associated Vasculitis (AAV)

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated Vasculitis

The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis

AYLo - AutoimmunitY and Loss of y

Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases

Rare AutoImmune SElf-management Programme Development